In 1987, we started octreotide receptor scintigraphy in humans. After a few years of using the radioiodinated [Tyrs]-octreotide,' we switched to [lllIn-DTPA-~-Phe*]octreotide, which has many advantages over the radioiodinated Patients with various forms of cancer, both classically known as neuroendocrine and nonendocrine, have been inve~tigated.~ The application of these new peptide-receptor ag...
